Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.

OBJECTIVE Clozapine's potent antagonism of muscarinic M1 receptors is thought to worsen working memory deficits associated with schizophrenia. In contrast, its major metabolite, N-desmethylclozapine (NDMC), is thought to enhance working memory via its M1 receptor agonist activity. The authors hypothesized that the ratio of serum clozapine and NDMC concentrations would be inversely associated with working memory performance in schizophrenia. METHOD Thirty patients with schizophrenia or schizoaffective disorder who were receiving clozapine monotherapy at bedtime completed the MATRICS Consensus Cognitive Battery (MCCB) on the day their blood was collected to assess concentrations of clozapine and NDMC as well as serum anticholinergic activity. RESULTS The clozapine/NDMC ratio was significantly and negatively associated with working memory performance after controlling for age, gender, education, and symptom severity. No significant associations were found between individual clozapine and NDMC concentrations and working memory performance. Serum anticholinergic activity was significantly associated with clozapine concentration, but not with working memory performance or NDMC concentration. No significant associations were found between any pharmacological measure and performance on other MCCB cognitive domains. CONCLUSIONS This hypothesis-driven study confirms that clozapine/NDMC ratio is a strong predictor of working memory performance in patients with schizophrenia. This finding suggests that manipulating the clozapine/NDMC ratio could enhance cognition in patients with schizophrenia treated with clozapine. It also supports the study of procholinergic agents, such as M1 receptor-positive allosteric modulators, to enhance cognition in schizophrenia.

[1]  R. Haier,et al.  Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia , 1994, Schizophrenia Research.

[2]  Martin Sarter,et al.  Leveraging the cortical cholinergic system to enhance attention , 2013, Neuropharmacology.

[3]  Lewis A. Opler,et al.  Reliability and validity of the positive and negative syndrome scale for schizophrenics , 1988, Psychiatry Research.

[4]  B. Roth,et al.  The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine’s actions? , 2005, Psychopharmacology.

[5]  R. Heinrichs,et al.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. , 1998, Neuropsychology.

[6]  B. Pollock,et al.  Relation of serum anticholinergicity to cognitive status in schizophrenia patients taking clozapine or risperidone. , 1998, The Journal of clinical psychiatry.

[7]  Herbert Y Meltzer,et al.  Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.

[8]  B. Pollock,et al.  Cholinergic pathways and cognition in patients with schizophrenia: A pilot study , 2012, Schizophrenia Research.

[9]  T. Giovannetti,et al.  Anticholinergicity and cognitive processing in chronic schizophrenia , 2001, Biological Psychology.

[10]  B. Pollock,et al.  Anticholinergic Activity of 107 Medications Commonly Used by Older Adults , 2008, Journal of the American Geriatrics Society.

[11]  Nancy Légaré,et al.  Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. , 2013, Medical hypotheses.

[12]  N. Sugimoto,et al.  Effects of clozapine and N-desmethylclozapine on synaptic transmission at hippocampal inhibitory and excitatory synapses , 2011, Brain Research.

[13]  B. Pollock,et al.  Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. , 2003, Archives of general psychiatry.

[14]  A. Hannan,et al.  Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse , 2008, Behavioural pharmacology.

[15]  B. Pollock,et al.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia , 2012, Psychiatry Research: Neuroimaging.

[16]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[17]  B. Pollock,et al.  Clozapine and Global Cognition in Schizophrenia , 2010, Journal of clinical psychopharmacology.

[18]  M. Hasselmo,et al.  Modes and Models of Forebrain Cholinergic Neuromodulation of Cognition , 2011, Neuropsychopharmacology.

[19]  T. Goldberg,et al.  The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia , 1993, British Journal of Psychiatry.

[20]  Michael F. Green,et al.  Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS , 2004, Schizophrenia Research.

[21]  Sophia Vinogradov,et al.  The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. , 2009, The American journal of psychiatry.

[22]  O. Wolkowitz,et al.  The Effects of Clozapine on Symptom Reduction, Neurocognitive Function, and Clinical Management in Treatment-Refractory State Hospital Schizophrenic Inpatients , 1996, Neuropsychopharmacology.

[23]  C. Lustig,et al.  Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments , 2012, Neuropharmacology.

[24]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[25]  S. Okuda,et al.  Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions , 2011, Brain Research Bulletin.

[26]  J. Lieberman,et al.  Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. , 2001, The American journal of psychiatry.

[27]  D. Freeman,et al.  Solid-phase extraction and high-performance liquid chromatographic analysis of clozapine and norclozapine in human plasma. , 1996, Therapeutic drug monitoring.

[28]  S. Maehara,et al.  Behavioral effects of N-desmethylclozapine on locomotor activity and sensorimotor gating function in mice—Possible involvement of muscarinic receptors , 2011, Brain Research.

[29]  Dominic P. Williams,et al.  Metabolism and bioactivation of clozapine by human liver in vitro. , 1995, The Journal of pharmacology and experimental therapeutics.

[30]  A. Levey,et al.  The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine , 2004, Psychopharmacology.

[31]  U. Bondesson,et al.  Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection , 2004, Psychopharmacology.

[32]  P. Jeffrey Conn,et al.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. Czobor,et al.  Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. , 1998, The Journal of clinical psychiatry.

[34]  A. Meyer-Lindenberg,et al.  Improvement of Cognitive Function in Schizophrenic Patients Receiving Clozapine or Zotepine: Results from a Double-Blind Study , 1997, Pharmacopsychiatry.

[35]  L. Bertilsson,et al.  The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. , 2003, British journal of clinical pharmacology.

[36]  Lewis Couchman,et al.  Plasma Clozapine, Norclozapine, and the Clozapine:Norclozapine Ratio in Relation to Prescribed Dose and Other Factors: Data From a Therapeutic Drug Monitoring Service, 1993–2007 , 2010, Therapeutic drug monitoring.

[37]  R. Buchanan,et al.  The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance , 1994, Biological Psychiatry.

[38]  S. Snyder,et al.  Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects. , 1974, Archives of general psychiatry.

[39]  H. Meltzer,et al.  N-Desmethylclozapine, a Major Metabolite of Clozapine, Increases Cortical Acetylcholine and Dopamine Release In Vivo Via Stimulation of M1 Muscarinic Receptors , 2005, Neuropsychopharmacology.

[40]  H. Meltzer,et al.  The influence of N-desmethylclozapine and clozapine on recognition memory and BDNF expression in hippocampus , 2011, Brain Research Bulletin.